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ABSTRACT 
The immunosuppressants FKSO6 and rapamycin 
bind to the same immunophilin, FKS06 binding protein 
(FKBP), and inhibit distinct signal transduction 
pathways in T lymphocytes. A nonnatural immuno- 
philin ligand, S06BD, which contains only the common 
structural elements of FKSO6 and rapamycin, was 
synthesized and found to be a high-afhity ligand of 
FKBP and a potent inhibitor of FKBP rotamase ac- 
tivity. Whereas 506BD does not interfere with T cell 
activation, it d m  block the immunosuppressive ef- 
fects of both F-6 and rapamycin. Thus, the common 
immunophilin binding element of these immunosup- 
pressants, which is responsible for rotamase inhi- 
bition, is fused to different effector elements, resulting 
in the inhibition of different signaling pathways. 
Inhibition of rotamase activity is an insufficient re- 
quirement for mediating these effects. 
COMMENTS 
Organ transplantation, despite numerous technical 
advances in surgical procedure, remains limited by graft 
rejection. The basis of rejection of foreign tissue or organ 
grafts arises from the immunological incompatibility of 
the donor and the recipient. This immunological incom- 
patibility is determined by a system of tissue antigens 
termed the major histocompatibility complex (MHC), 
which is expressed on virtually all cells (1). The human 
MHC system is termed HLA and contains at least six 
expressed genetic regions that belong to one of two major 
classes: class I, which includes the HLA-A, HLA-B and 
HLA-C regions, and class 11, which includes HLA-DR, 
HLA-DQ and HLA-DP. Class I genes are expressed on 
the surface of all nucleated cells, whereas class I1 genes 
are normally restricted in their distribution to antigen- 
presenting cells such as macrophages. Each locus is 
extremely polymorphic. From 6 to 30 distinct alleles 
have been discovered at any one locus, and thus two 
randomly chosen individuals are unlikely to be “HLA- 
identical.” T cells in the transplant recipient recognize 
and react to the foreign HLA antigens present on 
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available to T cells because class I MHC antigens are 
constituitively expressed on the surface of all nucleated 
cells. Furthermore, activation of many cell types (by 
inflammatory lymphokines or even by the “trauma” of 
transplantation) increases class I expression and can 
also induce the de nouo expression of class I1 MHC genes, 
processes that may increase the immunogenicity of the 
transplanted organ (2). 
The immunological response to foreign HLA antigens 
is orchestrated by T cells through the production of 
lymphokines. When activated, T cells secrete a number 
of lymphokines including interleukin 2 (IL-2). IL-2, in 
turn, supports the initial clonal expansion of 
lymphokine-secreting helper T cells and cytotoxic T 
cells. Together, IL-2 and other lymphokines, including 
tumor necrosis factor, interferon-? and IL-4, promote 
the activation and proliferation of mature effector cells 
such as monocytes and cytotoxic T cells and also induce 
B cells to generate specific opsonizing and complement- 
fixing antibodies. In the absence of immunosuppression, 
these events proceed vigorously and rapidly, leading to 
destruction of the transplanted tissue within days to 
weeks. 
For organ transplantation to be successful, some form 
of suppression of the host immune response is nec- 
essary. Initial studies performed with organic solvents 
and nitrogen mustards showed that these substances 
were effective at prolonging allograft survival, but they 
were too toxic for routine use. The development of 
6-mercaptopurine (of which azathioprine is a derivative) 
and its successful use in 1959 ushered in the modern era 
of immunosuppression. From then until the early 1980s, 
the combination of azathioprine and prednisone was the 
mainstay of pharmacological immunosuppression. 
However, both agents are relatively nonspecific, and the 
subsequent discovery and development of cyclosporine 
represented a significant advance in both specificity and 
efficacy. 
Cyclosporine, a fungal polypeptide, acts as an immu- 
nosuppressant by inhibiting helper T cells from pro- 
ducing IL-2 and other lymphokines (3). This prevents 
graft rejection by depriving immune effector cells of 
lymphokines required for their clonal expansion and/or 
activation. Whereas cyclosporine represents a signif- 
icant advance in therapy, its ability to suppress the 
immune system is incomplete. In addition, cyclosporine 
therapy has been associated with a number of side 
effects, particularly nephrotoxicity, that can limit its 
use. Thus the search for new immunosuppressants 
continues, focusing on agents with nonoverlapping 
toxicities and on those with distinct mechanisms of 
action. In particular, the latter might be useful in 
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designing combination regimens that block distinct 
phases of the immune response. To this end, much 
research is directed toward determining the mechanism 
of action of these drugs, and these studies can also lead 
to important insights into the physiological processes of 
the immune system. For example, in 1984, Handschu- 
maker et al. (4) described a cyclosporine-binding protein 
present in the cell cytosol termed cyclophilin. Cyclo- 
philin, or its closely related isoforms, is found in 
virtually all mammalian cell types and in fungi, yeast 
and plants. Subsequent studies demonstrated that 
cyclophilin was a cis-trans peptidyl-prolyl isomerase, 
an enzyme that catalyzes the interconversion of the 
cis-rotamers and trans-rotamers of peptidyl-prolyl 
amide bonds, thus assisting in protein folding (5, 6). 
Cyclosporine blocks the isomerase activity of cyclo- 
philin, an effect that is necessary but not sufficient 
for its immunosuppressive activity. How this leads to 
the inhibition of IL-2 gene transcription is not yet 
known. 
Recently, a number of studies have been published 
that investigate the mechanism of action of two rela- 
tively new agents, FK 506 and rapamycin. Together, 
they present a cautionary tale. Although structurally 
dissimilar, FK 506 appears to act in a very similar 
fashion as cyclosporine, blocking IL-2 gene transcription 
after T-cell activation (7). Furthermore, FK 506 binds to 
a cytoplasmic enzyme (FK 506-binding protein or 
FKBP) distinct from cyclophilin but that also acts as a 
cis-trans peptidyl-prolyl isomerase ( 7). Like cyclo- 
sporine, FK 506 blocks the rotamase activity of its 
binding protein, and neither drug affects the activity of 
the other rotamase. On the basis of this data, one might 
predict that cyclosporine and FK 506 would have 
additive effects in uiuo, and this has indeed been shown 
in preliminary studies of murine s h n  and canine renal 
allografts (8, 9). 
The discovery of FK 506 renewed interest in ra- 
pamycin, which, like FK 506, is a macrolide antibiotic 
with immunosuppressant properties. However, despite 
this structural similarity rapamycin has a ls t inct  site of 
action: blockade of the response to IL-2 without inter- 
feringwith IL-2 production (7). The fact that rapamycin 
acted at a phase of the immune response distinct from 
that of cyclosporine or FK 506 suggested that it might 
have synergistic effects when used in uivo in combi- 
nation with either of these agents. This is probably true 
for cyclosporine; however, the combination of FK 506 
and rapamycin appears to be more complicated. Despite 
their distinct modes of action, FK 506 and rapamycin 
can act as reciprocal antagonists in uitro (10). This 
finding, coupled with their common chemical structure, 
led to the suggestion that FK 506 and rapamycin might 
share a common intracellular binding protein, thereby 
accounting for their reciprocal antagonism, and this has 
now been confirmed. 
In this article, Bierer et al. have built on these 
observations by synthesizing an analog of FK 506 
termed 506BD. In synthesizing 506BD, the authors 
attempted to retain the rotamase-binding domain of FK 
506 but eliminate additional structural elements. Like 
FK 506, 506BD also bound to FK 506-binding protein 
and blocked its rotamase activity; however, 506BD did 
not interfere with T-cell activation in uitro or the 
production of IL-2. Previous work by this group dem- 
onstrated that rapamycin also blocks FKBP rotamase 
activity, even though rapamycin does not affect IL-2 
gene transcription (1 1). These findings demonstrate 
that inhibition of the rotamase activity of FK 506- 
binding protein is by itself insufficient to mediate the 
biological activity of FK 506. 
Bierer et al. next investigated whether their inactive 
compound, 506BD, could block the activity of FK 506 or 
rapamycin. When added at  a 100-fold excess, 506BD was 
able to block the immunosuppressive action of FK 506, 
presumably by lsplacing FK 506 from its binding 
protein. As expected, because they bind to different 
rotamases, 506BD had no effect on the ability of 
cyclosporine to inhibit the same responses (T-cell pro- 
liferation, IL-2 production). Importantly, 506BD also 
blocked the immunosuppressive effects of rapamycin, 
although again a 100-fold excess of 506BD was required. 
These data suggest a model whereby FK 506 and 
rapamycin each bind to FK 506-binding protein at the 
same site using similar structural motifs but that the 
resulting drug-protein complexes use additional and 
functionally distinct domains to exert their effects on 
dlfferent target molecules. These target molecules 
would regulate different signal transduction pathways, 
one initiated on T-cell activation that induces the 
transcription of lymphohne genes such as IL-2 and one 
that results in cell proliferation as a result of IL-2 
binding to its cell surface receptor. 
The identification of cyclophilin as a protein with 
cis-trans peptidyl-prolyl rotamase activity seemed cu- 
rious at  the time because no role for this activity in 
lympholune gene induction was known. It was similarly 
surprising that both FK 506 and rapamycin bound to a 
protein with similar activity, particularly when they had 
dstinct effects. The demonstration by Bierer et al. that 
inhibition of rotamase activity is apparently by itself 
insufficient for the action of these agents solves one 
problem but raises another. That is, how does the 
drug-rotamase complex interfere with T-cell responses? 
Even at high concentrations of rapamycin or FK 506, 
most FKBP remains unbound by the drug, which is 
consistent with the finding that inhibition of rotamase 
activity is not itself the target action of rapamycin or FK 
506 but rather that the drug-FKBP complex is respon- 
sible for the observed effects. Bierer, et d .  also present 
evidence that whereas high concentrations of FK 506 
and rapamycin are antagonistic of each others actions 
(blockade of IL-2 production or IL-2-dependent T-cell 
proliferation, respectively), at low concentrations FK 
506 and rapamycin can have an additive effect on T-cell 
activation. The fact that FK 506 and rapamycin exert 
their effects a t  different points in the T-cell activation 
cascade (blockade of IL-2 production or IL-Mependent 
T-cell proliferation, respectively), suggests that the FK 
506-FKBP complex and the rapamycin-FKBP complex 
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have distinct intracellular targets. A recent report 
(Goebl MG, Cell 1991; 64:1051-1052, Correspondence), 
tentatively identifying FKBP as a previously described 
12 kD endogenous inhibitor of protein kinase C, raises 
the possibility that FK 506 exerts its effect by blocking 
activation of protein kinase C, a key step in antigen- 
induced T-cell activation. One possible model inte- 
grating this report with the work of Bierer et al. would 
be that FK 506 must bind to FKBP to elicit the protein 
kinase C inhibitory capacity of FKBP. FK 506 might 
activate FKBP by a conformational change or by 
directing FKBP to the proper subcellular compartment. 
In either case, only the FK 506-FKBP complex is 
effective. Presumably, the rapamycin-FKBP complex 
acts in a different fashion or at a distinct intracellular 
site. 
These studies highlight how much has been learned in 
recent years of the molecular events initiated by T-cell 
activation. They also underscore the complexity of the 
immune response and the risks of predicting drug effects 
based solely on chemical similarities. Furthermore, the 
difficulty in determining whether drugs with apparently 
distinct effects in vitro will be useful in combination 
should serve to emphasize that there is no substitute for 
rigorous in  vivo testing. Ultimately, the goal of trans- 
plantation research is to induce a state of tolerance, or 
immunological unresponsiveness, to the graft. Although 
this remains an elusive goal, studies such as these 
advance us one step further by dissecting intracellular 
events that occur during the immune response. 
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SPLIT-LIVER TRANSPLANTATION: ONE PLUS ONE 
DOESN’T ALWAYS EQUAL TWO 
Emond JC, Whitington PF, Thistlewaite JR ,  Cherqui D, 
Alonso EA, Woodle IS, Vogelbach P, et al. Transplan- 
tation of two patients with one liver: Analysis of a 
preliminary experience with “split-liver” grafting. Ann 
Surg 1990;212:14-22. 
ABSTRACT 
Surgical reduction of donor livers to treat small 
children has been performed successfully in several 
centers. While this procedure improves the allocation 
of livers, it does not increase the organ supply. We have 
extended reduced-size orthotopic liver transplan- 
tation (OLT) to treat 18 patients with 9 livers, ac- 
counting for 26% of our transplants during a 10-month 
period and have evaluated the results. In 18 split liver 
OLTs, patient survival was 67% and graft survival was 
50%. In comparison, for 34 patients treated with 
full-size OLT during the same period, patient survival 
was 84% (p = 0.298) and graft survival was 76% 
(p = 0.126). Biliary complications were significantly 
more frequent in split grafts, occurring in 27%, as 
compared to 4% in full-sized grafts (p = 0.017). Primary 
nonfunction (4% versus 5.5%) and arterial thrombosis 
(6% versus 9%) occurred with similar frequency in split 
and full-size OLT (p = not significant). These results 
demonstrated that split-liver OLT is feasible and could 
have a substantial impact in transplant practice. We 
believe that biliary complications can be prevented by 
technical improvements and that split-liver OLT will 
improve transplant therapy by making more livers 
available. 
Broelsch CE, Emond JC, Whitington PF, Thistlethwaite 
JR ,  Baker AL, Lichtor JL. Application of reduced-size 
liver transplants as split grafts, auxiliary orthotopic 
grafts, and living related segmental transplants. Ann 
Surg 1990;212:368-375. 
ABSTRACT 
The University of Chicago program in pediatric liver 
transplantation continues actively to seek innovative 
surgical solutions to problems related to the man- 
agement of children with end-stage liver disease. 
Among the most important problems facing these 
children is a shortage of donor organs, which results 
from three factors in addition to the actual supply of 
